United Therapeutics' (UTHR) phase 3 trial of ralinepag in patients with pulmonary arterial hypertension met its primary endpoint, the company said Sunday.

The treatment cut the risk of clinical worsening events by 55%, compared with placebo, with secondary endpoints also demonstrating favorable outcomes, the company said.

United Therapeutics plans to file a new drug application with the US Food and Drug Administration for ralinepag in H2 2026.

Pulmonary arterial hypertension is a life-threatening disease that impacts the blood vessels in the lungs and is characterized by increased pressure in the pulmonary arteries.